[fright]
[/fright]Dr. Natelson has been absorbed by the differences between chronic fatigue syndrome (ME/CFS) and fibromyalgia for quite some time. In fact, one could say that Natelson is absorbed by differences.
He is equally interested between the differences between people with ME/CFS and those with ME/CFS and FM. He's also fascinated by the differences between ME/CFS patients who have and don't have depression. He has, for instance, found that ME/CFS patients without depression have more neurological abnormalities than ME/CFS patients with depression.
In short, Natelson is something of a splitter. He believes in precision and abhors lumping diseases or subsets of diseases together.
His emphasis on splitting is not just philosophical, though. Natelson has been around long enough to know a disturbing trend line when he sees one. He believes that the increasing emphasis on broadening the diagnostic criteria for fibromyalgia could have very negative consequences both for it and for ME/CFS.
He's out to put a stop to this lumping trend, and he recently penned a review to that end. In it he examined studies which compared the two diseases. Not many comparative studies have been done but the some differences have emerged.
QJM. 2013 Jan;106(1):3-9. doi: 10.1093/qjmed/hcs156. Epub 2012 Aug 26. Is chronic fatigue syndrome the same illness as fibromyalgia: evaluating the 'single syndrome' hypothesis. Abbi B1, Natelson BH.
Differences Between Fibromyalgia and Chronic Fatigue Syndrome
FM
Natelson believes that the 2010 diagnostic for criteria for FM (still listed as preliminary) essentially removes the distinction between ME/CFS and FM. Under those criteria many ME/CFS patients can and probably are being diagnosed as having fibromyalgia. (A DePaul study suggests that over 50% would be.) That could, over the long term, possibly lead to the disappearance or diminishment of ME/CFS as a separate disease.
The 2010 ACR criteria for FM are the picture of simplicity:
[fleft]
[/fleft]Sharing similar symptoms with a much larger disease could be problematic if the two diseases are not precisely differentiated. Not only is fibromyalgia much more prevalent than ME/CFS (10 million people- - 1 million in the U.S), but the FDA approved drugs for it and the commercials featuring those drugs means that virtually everyone has heard of fibromyalgia.
Because doctors are much more familiar with FM than ME/CFS they are more likely, if given the chance, to diagnose a patient with FM. The ACR 2010 criteria gives doctors that chance.
The broad diagnostic criteria for FM could, conceivably, create a long term challenge to the viability of ME/CFS. If ME/CFS patients keep getting thrown into the FM basket the support for the ME/CFS community could weaken over time.)
In fact, Natelson believes that the less restrictive diagnostic criteria for FM (which has no exclusionary conditions) may be partly responsible for the greatly increased prevalence of FM relative to ME/CFS.
(Notice the different trend lines in the diseases; the ME/CFS diagnostic criteria are getting narrower and more precise over time while the FM diagnostic criteria are getting broader. Ferreting out subsets is at the top of the ME/CFS agenda, but that topic hardly seems to be on radar screens of FM researchers.
In fact, broadening a disease's diagnostic criteria may be unusual in the medical world. The diagnostic criteria for headache, migraine and cancer and many other diseases are continually being refined. That increased precision has paid off in better treatment for patients. Precision medicine - which attempts to place the individual in the context of their disease - is now believed to be the future of medicine.
A Trend Towards Somatization?
The creation of a kind of super-syndrome that results in ME/CFS being put into the FM basket risks, would, Natelson believes, at the very least, result in some patients being diagnosed with having a somatization disorder.
Natelson has found that the diagnosis of a somatization disorder depends entirely on how a doctors interprets a patients symptoms. If a doctor codes them as having a physical origin they get a physical diagnosis, but if a doctor codes the symptoms has having a mental origin, almost 100% of ME/CFS patients are diagnosed as having a somatization disorder.
[fright]
[/fright]ME/CFS patients who have "extra symptoms" which don't fit broader diagnostic protocols would be in danger of slipping through the cracks (once again) diagnosed as having a somatization disorder by a psychiatrist. Natelson clearly believes that these unusual symptoms have a physiological origin and that they be explored not dismissed.
In fact, Natelson believes that lumping the two diseases together will make them prone to being diagnosed as somatization disorders. He strongly recommends that the individual differences between the two continue to be teased apart. That will, he believes, lead to a continued focus on finding the pathophysiological causes present in these diseases.
Will Chronic Fatigue Syndrome Lead the Way?
I believe that important insights into the cause of ME/CFS will stop it from being further subsumed into FM. The emphasis on deep molecular analyses to uncover biomarkers and subsets will carry the day, and could even lead to a reassessment of FM. As the biomarkers for ME/CFS emerge, a significant number of people with fibromyalgia will be reclassified as having ME/CFS.
That will require, though, the two research communities finally starting to collaborate. Despite their symptomatic similarities Natelson points out how segregated these diseases have been in the lab. Very few FM researchers study ME/CFS and vice versa. Natelson relayed that when he ran his NIH ME/CFS research center he was actually prohibited from including FM patients in his studies.
The way out of the current jumbled FM and ME/CFS morass, he believes, is to do what the AHRQ study and P2P reports recommended; break up the silo's and regularly include FM and ME/CFS (and other) patients in the same studies. Given the new approach the NIH is taking and the reinvention of the ME/CFS field that is occurring, that will hopefully be done as a matter of course. When that occurs the concerns that ME/CFS will continue to get subsumed into FM will disappear.
A bigger concern, right now, is FM itself; it's still a rich research field but the emphasis in ME/CFS on networking and collaborating to understand the molecular underpinnings of the disease is not present.
With the NIH more and more focused on the problem of pain, FM research should be ascendant but for some reason it's not. Instead, FM is losing its way in the NIH a bit. It's sponsor at the NIH (NIAMS) is almost wholly focused on behavioral disorders. That's almost unthinkable in ME/CFS partially because of the outcry it would raise in the patient community. This is not to say that there's not a lot of wonderful FM research; there is - but it could be better.
Natelson's editorial highlights a singularly important factor for multi-symptomatic, poorly understood diseases like ME/CFS and FM that can all too easily be shoved into a psychological box because they don't fit standard categories: precision is key and lumping is out.
He is equally interested between the differences between people with ME/CFS and those with ME/CFS and FM. He's also fascinated by the differences between ME/CFS patients who have and don't have depression. He has, for instance, found that ME/CFS patients without depression have more neurological abnormalities than ME/CFS patients with depression.
In short, Natelson is something of a splitter. He believes in precision and abhors lumping diseases or subsets of diseases together.
His emphasis on splitting is not just philosophical, though. Natelson has been around long enough to know a disturbing trend line when he sees one. He believes that the increasing emphasis on broadening the diagnostic criteria for fibromyalgia could have very negative consequences both for it and for ME/CFS.
He's out to put a stop to this lumping trend, and he recently penned a review to that end. In it he examined studies which compared the two diseases. Not many comparative studies have been done but the some differences have emerged.
QJM. 2013 Jan;106(1):3-9. doi: 10.1093/qjmed/hcs156. Epub 2012 Aug 26. Is chronic fatigue syndrome the same illness as fibromyalgia: evaluating the 'single syndrome' hypothesis. Abbi B1, Natelson BH.
Differences Between Fibromyalgia and Chronic Fatigue Syndrome
FM
- Growth hormone problems present in FM
- Normal or increased cortisol relative to ME/CFS
- Plasma melatonin levels higher in FM
- RNase L protein not unusually fragmented
- Less abnormal gene expression responses to exercise plus increased expression of ion channel genes at baseline. (Light studies)
- Autonomic nervous system - both diseases have low HRV variability but more extensive studies revealed FM patients have higher blood pressure during tilt than controls or ME/CFS patients. ME/CFS and FM patients and healthy controls all have different "hemo-instability indices".
- Electrophoretic analysis of urine produces different biomarkers in the two diseases.
- Growth hormone problems probably not present
- Decreased cortisol production particularly in morning.
- Increased fragmentation of RNase L protein
- Highly abnormal gene expression increased expression of sensory, adrenergic and immune genes in response to exercise (Light studies)
- Autonomic nervous system - both have low HRV variability, but more extensive studies suggest that combined heart rate and blood pressure results are quite different.
- Electrophoretic analysis of urine produces different biomarkers in the two diseases.
Natelson believes that the 2010 diagnostic for criteria for FM (still listed as preliminary) essentially removes the distinction between ME/CFS and FM. Under those criteria many ME/CFS patients can and probably are being diagnosed as having fibromyalgia. (A DePaul study suggests that over 50% would be.) That could, over the long term, possibly lead to the disappearance or diminishment of ME/CFS as a separate disease.
The 2010 ACR criteria for FM are the picture of simplicity:
- Widespread pain index (WPI) > or + to 7 and a symptom severity score > or = to 5, or a widespread pain index from 3-6 and a symptom severity score > or = to 9.
- Symptoms have been present at a similar level for at least 3 months.
- The patient does not have a disorder that would otherwise explain the pain.
[fleft]
Because doctors are much more familiar with FM than ME/CFS they are more likely, if given the chance, to diagnose a patient with FM. The ACR 2010 criteria gives doctors that chance.
The broad diagnostic criteria for FM could, conceivably, create a long term challenge to the viability of ME/CFS. If ME/CFS patients keep getting thrown into the FM basket the support for the ME/CFS community could weaken over time.)
In fact, Natelson believes that the less restrictive diagnostic criteria for FM (which has no exclusionary conditions) may be partly responsible for the greatly increased prevalence of FM relative to ME/CFS.
(Notice the different trend lines in the diseases; the ME/CFS diagnostic criteria are getting narrower and more precise over time while the FM diagnostic criteria are getting broader. Ferreting out subsets is at the top of the ME/CFS agenda, but that topic hardly seems to be on radar screens of FM researchers.
In fact, broadening a disease's diagnostic criteria may be unusual in the medical world. The diagnostic criteria for headache, migraine and cancer and many other diseases are continually being refined. That increased precision has paid off in better treatment for patients. Precision medicine - which attempts to place the individual in the context of their disease - is now believed to be the future of medicine.
A Trend Towards Somatization?
The creation of a kind of super-syndrome that results in ME/CFS being put into the FM basket risks, would, Natelson believes, at the very least, result in some patients being diagnosed with having a somatization disorder.
Natelson has found that the diagnosis of a somatization disorder depends entirely on how a doctors interprets a patients symptoms. If a doctor codes them as having a physical origin they get a physical diagnosis, but if a doctor codes the symptoms has having a mental origin, almost 100% of ME/CFS patients are diagnosed as having a somatization disorder.
[fright]
In fact, Natelson believes that lumping the two diseases together will make them prone to being diagnosed as somatization disorders. He strongly recommends that the individual differences between the two continue to be teased apart. That will, he believes, lead to a continued focus on finding the pathophysiological causes present in these diseases.
Will Chronic Fatigue Syndrome Lead the Way?
I believe that important insights into the cause of ME/CFS will stop it from being further subsumed into FM. The emphasis on deep molecular analyses to uncover biomarkers and subsets will carry the day, and could even lead to a reassessment of FM. As the biomarkers for ME/CFS emerge, a significant number of people with fibromyalgia will be reclassified as having ME/CFS.
That will require, though, the two research communities finally starting to collaborate. Despite their symptomatic similarities Natelson points out how segregated these diseases have been in the lab. Very few FM researchers study ME/CFS and vice versa. Natelson relayed that when he ran his NIH ME/CFS research center he was actually prohibited from including FM patients in his studies.
The way out of the current jumbled FM and ME/CFS morass, he believes, is to do what the AHRQ study and P2P reports recommended; break up the silo's and regularly include FM and ME/CFS (and other) patients in the same studies. Given the new approach the NIH is taking and the reinvention of the ME/CFS field that is occurring, that will hopefully be done as a matter of course. When that occurs the concerns that ME/CFS will continue to get subsumed into FM will disappear.
A bigger concern, right now, is FM itself; it's still a rich research field but the emphasis in ME/CFS on networking and collaborating to understand the molecular underpinnings of the disease is not present.
With the NIH more and more focused on the problem of pain, FM research should be ascendant but for some reason it's not. Instead, FM is losing its way in the NIH a bit. It's sponsor at the NIH (NIAMS) is almost wholly focused on behavioral disorders. That's almost unthinkable in ME/CFS partially because of the outcry it would raise in the patient community. This is not to say that there's not a lot of wonderful FM research; there is - but it could be better.
Natelson's editorial highlights a singularly important factor for multi-symptomatic, poorly understood diseases like ME/CFS and FM that can all too easily be shoved into a psychological box because they don't fit standard categories: precision is key and lumping is out.
Last edited: